| Project/Area Number |
20K09938
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 57030:Conservative dentistry-related
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
大森 一弘 岡山大学, 医歯薬学域, 准教授 (20549860)
山城 圭介 岡山大学, 大学病院, 講師 (30581087)
高柴 正悟 岡山大学, 医歯薬学域, 教授 (50226768)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | Vital pulp therapy / Resolvin D2 / Reparative dentin / Dental pulp cell / Resolving D2 / Dental pulp cells / Resolvin D2 (RVD2) / Dentin regeneration / pulp capping / lipid mediator |
|---|
| Outline of Research at the Start |
Resolvins are a new bioactive products of omega-3 fatty acid produced by macrophages, endothelial cells, dental pulp stem cells- that counter pro-inflammatory, pro-resolution signals, promote hard tissue regeneration, re-vascularization and control inflammatory pain. Here, we hypothesize that RvD2 will be a good candidate as a regenerative pulp capping material because it could regulate the inflammation of the pulp exposed site, control the pain, stimulate reparative dentine formation, improve neo vascularization and promote bacterial clearance.
|
| Outline of Final Research Achievements |
RvD2 applied directly to the pulpal surface, induced reparative dentin (RD) formation. The possible mechanism may be related to the RvD2-induced secretion of cytokines related to tissue regeneration such as VEGF and TGF-β in the pulp tissue thus promoting cell proliferation. RvD2 also decreased the TRAP1 pain receptor gene expression thus suppressing pain. These results suggest that RvD2 can be used for Vital pulp therapy (VPT) and may exert reparative actions by a mechanism different from that of existing VPT reagents, which do not induce inflammation. We conclude that RvD2 could be a material for the next generation VTP, comparable to pulp stem cell transplantation-based therapies.
|
| Academic Significance and Societal Importance of the Research Achievements |
We probed that RvD2 can be the ideal candidate for vital pulp therapy because it is a natural compound produced by several cells during the resolution of the inflammation phase, having anti-inflammatory properties, stimulating reparative dentin, and reducing pain.
|
